Trending...
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- Beijing Review: ChASC5 Bridging Hearts Across The Pacific
- BMCC Tribeca PAC Presents New Season of Music, Theater & Family Fun
NEW YORK, Oct. 23, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the "Company")
SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company had been conducting a clinical trial to evaluate the efficacy and safety of TPOXX (aka tecovirimat) in the treatment of mpox in combination with standard of care. On August 15, 2024, the preliminary analysis of the PALM 007 clinical trial revealed that TPOXX had failed to achieve its primary endpoint.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Dr. Jay Varma, SIGA's Chief Medical Officer and Executive Vice President, was fired from his position following an investigative report that uncovered him on video publicly bragging about hosting sex parties while serving as a senior health adviser to former Mayor Bill de Blasio and attending an underground rave party in New York at the height of the COVID pandemic.
More on Nyenta.com
After the close of trading on September 23, 2024, the Company filed a form 8-K with the United States Securities and Exchange Commission ("SEC") stating:
"Pursuant to the terms of his employment agreement, Dr. Varma's service on the Company's Board of Directors also automatically ended effective immediately, which is required when an event occurs that is deemed to affect public-company shareholders."
On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial. According to Dr. Varma, the media "spin" campaign was designed to convince investors "not to dump the stock, thinking that the Company was worthless" while conceding that pursuit of TPOXX as a treatment for mpox might not even be worth it because "there's only a few thousand cases in the United States."
The stock declined 15.73% on September 25th, closing at $6.75, down $1.26 per share.
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
More on Nyenta.com
If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company had been conducting a clinical trial to evaluate the efficacy and safety of TPOXX (aka tecovirimat) in the treatment of mpox in combination with standard of care. On August 15, 2024, the preliminary analysis of the PALM 007 clinical trial revealed that TPOXX had failed to achieve its primary endpoint.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Dr. Jay Varma, SIGA's Chief Medical Officer and Executive Vice President, was fired from his position following an investigative report that uncovered him on video publicly bragging about hosting sex parties while serving as a senior health adviser to former Mayor Bill de Blasio and attending an underground rave party in New York at the height of the COVID pandemic.
More on Nyenta.com
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: FL, STRM, TXNM, and CTLP
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- Happi Coffee Launches with a Mission to Bring Freshness, Simplicity, and Intention to Your Daily Cup
- SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Krispy Kreme
After the close of trading on September 23, 2024, the Company filed a form 8-K with the United States Securities and Exchange Commission ("SEC") stating:
"Pursuant to the terms of his employment agreement, Dr. Varma's service on the Company's Board of Directors also automatically ended effective immediately, which is required when an event occurs that is deemed to affect public-company shareholders."
On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial. According to Dr. Varma, the media "spin" campaign was designed to convince investors "not to dump the stock, thinking that the Company was worthless" while conceding that pursuit of TPOXX as a treatment for mpox might not even be worth it because "there's only a few thousand cases in the United States."
The stock declined 15.73% on September 25th, closing at $6.75, down $1.26 per share.
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
More on Nyenta.com
- Local firm Launches QuickBooks Support to Help Small Businesses Streamline Finances and Boost Growth
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- Natcast Celebrates Grand Opening of NSTC EUV Accelerator at NY CREATES' Albany NanoTech Complex, One of Three NSTC Flagship Semiconductor R&D Facilities Across the Country
- Don't Let a Lawsuit Take Away Everything: Attorney Blake Harris Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- New Book Executive One Chronicles the Visionary Leadership of Ernest E. Middleton, PhD
If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
Filed Under: Business
0 Comments
Latest on Nyenta.com
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: HSON, ENZB, and BRZH
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Momentum Commerce Tracking of Amazon US Prime Day Sales Shows +165% Increase on Day 3, Path to Year-over-Year Growth
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Olson's Walk-Off Hit Gives N.L. All-Star Game Triumph In Strat-O-Matic Simulation
- Beijing Review: ChASC5 Bridging Hearts Across The Pacific
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Rod Joseph Honored at First International Day of Hope in New York City
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Tronox Announces Dates for Second Quarter 2025 Earnings Release & Webcast Conference Call
- Colbert Packaging Announces WBENC Recognition
- Non-Profit Pay Away Announces Support to Boys & Girls Clubs of America for Back-to-School Giving
- RBLP Leadership Certifications is authorizing new Training Partners in New York
- BMCC Tribeca PAC Presents New Season of Music, Theater & Family Fun
- CPAmerica welcomes Trullion as a new Preferred Provider, supporting modernized accounting processes